Sign Up Today and Learn More About Dewpoint Therapeutics Stock
Invest in or calculate the value of your shares in Dewpoint Therapeutics or other pre-IPO companies through EquityZen's platform.
Dewpoint Therapeutics Stock
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
About Dewpoint Therapeutics Stock
Founded
2018
Headquarters
Boston, MA, US
Industries
Travel and Tourism, Manufacturing, Space
Dewpoint Therapeutics Press Mentions
Stay in the know about the latest news on Dewpoint Therapeutics
FDA Grants Fast Track Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
globenewswire • Nov 18, 2025
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
morningstar • Nov 05, 2025
FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
globenewswire • Oct 30, 2025
Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers
globenewswire • Oct 21, 2025
Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025
globenewswire • Oct 14, 2025
Dewpoint Therapeutics Management
Leadership team at Dewpoint Therapeutics
Co Founder
Anthony Hyman
Chief Executive Officer
Ameet Nathwani
Join now and verify your accreditation status to gain access to:
- Dewpoint Therapeutics Current Valuation
- Dewpoint Therapeutics Stock Price
- Dewpoint Therapeutics Management
- Available deals in Dewpoint Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Dewpoint Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Dewpoint Therapeutics Revenue and Financials
- Dewpoint Therapeutics Highlights
- Dewpoint Therapeutics Business Model
- Dewpoint Therapeutics Risk Factors
- Dewpoint Therapeutics Research Report from SACRA Research
Trading Dewpoint Therapeutics Stock
How to invest in Dewpoint Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Dewpoint Therapeutics through EquityZen funds. These investments are made available by existing Dewpoint Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Dewpoint Therapeutics stock?
Shareholders can sell their Dewpoint Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."